{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:22:41Z","timestamp":1776882161981,"version":"3.51.2"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case\u2013control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese. Finally, twenty-five studies were included in this meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD\u2009=\u20091.62, 95% CI 1.08 to 2.25, P\u2009=\u20090.000; GDM: SMD\u2009=\u20092.85, 95% CI 1.01 to 4.70, P\u2009=\u20090.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD\u2009=\u20091.58, 95% CI 0.59 to 2.56, P\u2009=\u20090.002; microalbuminuria: SMD\u2009=\u20092.57, 95% CI 0.92 to 4.22, P\u2009=\u20090.002; macroalbuminuria: SMD\u2009=\u20092.69, 95% CI 1.40 to 3.98, P\u2009=\u20090.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD\u2009=\u20091.49, 95% CI 0.28 to 2.71, P\u2009=\u20090.016; macroalbuminuria vs microalbuminuria: SMD\u2009=\u20090.93, 95% CI 0.34 to 1.52, P\u2009=\u20090.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our current meta-analysis demonstrates that serum level of YKL-40 is increased in DM and positively associated with the severe degree of albuminuria. Therefore, we suggest that YKL-40 could be considered to be detected, along with other inflammatory markers, if DM, especially DN, is suspected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-021-00624-9","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T22:02:42Z","timestamp":1610661762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6424-021X","authenticated-orcid":false,"given":"Wanwan","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaixing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"Suppl 1","key":"624_CR1","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2337\/dc13-S067","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(Suppl 1):S67-74.","journal-title":"Diabetes Care"},{"key":"624_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney Foundation","year":"2012","unstructured":"National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850\u201386.","journal-title":"Am J Kidney Dis"},{"key":"624_CR3","doi-asserted-by":"publisher","first-page":"e2841","DOI":"10.1002\/dmrr.2841","volume":"33","author":"N Papadopoulou-Marketou","year":"2017","unstructured":"Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metabol Res Rev. 2017;33:e2841.","journal-title":"Diabetes Metabol Res Rev"},{"key":"624_CR4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.23736\/S0026-4806.17.05496-9","volume":"109","author":"N Papadopoulou-Marketou","year":"2018","unstructured":"Papadopoulou-Marketou N, Paschou SA, Marketos N, Adamidi S, Adamidis S, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes. Minerva Med. 2018;109:218\u201328.","journal-title":"Minerva Med"},{"key":"624_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11892-013-0375-y","volume":"13","author":"E Lontchi-Yimagou","year":"2013","unstructured":"Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr DiabRep. 2013;13:435\u201344.","journal-title":"Curr DiabRep"},{"key":"624_CR6","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.dsx.2019.01.040","volume":"13","author":"M Halim","year":"2019","unstructured":"Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metabol Syndrome. 2019;13:1165\u201372.","journal-title":"Diabetes Metabol Syndrome"},{"key":"624_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s12035-015-9667-3","volume":"54","author":"P Kumar","year":"2017","unstructured":"Kumar P, Raman T, Swain MM, Mishra R, Pal A. Hyperglycemia-induced oxidative-nitrosative stress induces inflammation and neurodegeneration via augmented tuberous sclerosis complex-2 (TSC-2) activation in neuronal cells. Mol Neurobiol. 2017;54:238\u201354.","journal-title":"Mol Neurobiol"},{"key":"624_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2016.11.003","volume":"108","author":"SC Chang","year":"2016","unstructured":"Chang SC, Yang WV. Hyperglycemia, tumorigenesis, and chronic inflammation. Critic Rev oncol hematol. 2016;108:146\u201353.","journal-title":"Critic Rev oncol hematol"},{"key":"624_CR9","first-page":"351","volume":"110","author":"B Volck","year":"1998","unstructured":"Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351\u201360.","journal-title":"Proc Assoc Am Physicians"},{"key":"624_CR10","doi-asserted-by":"publisher","first-page":"44058","DOI":"10.1074\/jbc.M306792200","volume":"278","author":"M Rehli","year":"2003","unstructured":"Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058\u201367.","journal-title":"J Biol Chem"},{"key":"624_CR11","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9","volume":"43","author":"D Baeten","year":"2000","unstructured":"Baeten D, Boots AM, Steenbakkers PG, Elewaut D, Bos E, Verheijden GF, et al. Human cartilage gp-39+, CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum. 2000;43:1233\u201343.","journal-title":"Arthritis Rheum"},{"key":"624_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00011-006-0076-y","volume":"55","author":"CN Rathcke","year":"2006","unstructured":"Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflammat Res. 2006;55:221\u20137.","journal-title":"Inflammat Res"},{"key":"624_CR13","doi-asserted-by":"publisher","first-page":"18596","DOI":"10.4238\/2015.December.28.7","volume":"14","author":"JY Han","year":"2015","unstructured":"Han JY, Ma XY, Yu LJ, Shao Y, Wang QY. Correlation between serum YKL-40 levels and albuminuria in type 2 diabetes. Genet Mol Res. 2015;14:18596\u2013603.","journal-title":"Genet Mol Res"},{"key":"624_CR14","first-page":"225","volume":"30","author":"JY Han","year":"2014","unstructured":"Han JY, Shao Y, Wang QY. The correlation of serum YKL-40 and albuminuria in type 2 diabetes. Chinese J Endocrinol Metabol. 2014;30:225\u20137.","journal-title":"Chinese J Endocrinol Metabol."},{"key":"624_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3109\/09513590.2015.1126707","volume":"32","author":"J Li","year":"2016","unstructured":"Li J, Niu G, Wang H, Wang K, Huang B, Li M. Serum YKL-40 levels in gestational diabetes mellitus. Gynecol Endocrinol. 2016;32:412\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"624_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00011-005-0010-8","volume":"55","author":"CN Rathcke","year":"2006","unstructured":"Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflammat Res. 2006;55:53\u20139.","journal-title":"Inflammat Res"},{"key":"624_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1475-2840-9-86","volume":"9","author":"SB Thomsen","year":"2010","unstructured":"Thomsen SB, Rathcke CN, Zerahn B, Vestergaard H. Increased levels of the calcification marker matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc Diabetol. 2010;9:86.","journal-title":"Cardiovasc Diabetol"},{"key":"624_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1365-2362.2010.02274.x","volume":"40","author":"G Schaller","year":"2010","unstructured":"Schaller G, Brix JM, Placher-Sorko G, Hollerl F, Schernthaner GH, Schernthaner G. YKL-40 concentrations are not elevated in gestational diabetes. Eur J Clin Invest. 2010;40:339\u201343.","journal-title":"Eur J Clin Invest"},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1507\/endocrj.EJ12-0238","volume":"60","author":"F Sakamoto","year":"2013","unstructured":"Sakamoto F, Katakami N, Kaneto H, Yasuda T, Takahara M, Miyashita K, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. Endocr J. 2013;60:73\u20139.","journal-title":"Endocr J"},{"key":"624_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jri.2015.06.092","volume":"112","author":"AR Rinnov","year":"2015","unstructured":"Rinnov AR, Rathcke CN, Bonde L, Vilsboll T, Knop FK. Plasma YKL-40 during pregnancy and gestational diabetes mellitus. J Reprod Immunol. 2015;112:68\u201372.","journal-title":"J Reprod Immunol"},{"key":"624_CR21","first-page":"309","volume":"28","author":"SM Abd El Dayem","year":"2015","unstructured":"Abd El Dayem SM, Battah AA, El Shehaby A, Abd Allah N. Assessment of human cartilage glycoprotein 39 (YKL-40), preptin, and nitric oxide in adolescent patients with type 1 diabetes and its relation to cardiorenal affection. J Pediat Endocrinol Metabol. 2015;28:309\u201314.","journal-title":"J Pediat Endocrinol Metabol."},{"key":"624_CR22","doi-asserted-by":"crossref","unstructured":"Shiasi K, Talebian F, Khamechi SP, Nikoueinejad H, Sehat M, Azarbad Z, et al. Evaluation of YKL-40 serum level in patients with type 1 diabetes and its correlation with their metabolic and renal conditions. Nephro-Urol Month. 2017; 9.","DOI":"10.5812\/numonthly.12431"},{"issue":"11","key":"624_CR23","first-page":"4852","volume":"6","author":"D Rekha Kumari","year":"2015","unstructured":"Rekha Kumari D, Farid Babu M, Balu MK. Human cartilage glycoprotein 39 (YKL-40): a View in type 2 diabetes mellitus. Int J Pharm Sci Res. 2015;6(11):4852\u20136.","journal-title":"Int J Pharm Sci Res"},{"key":"624_CR24","first-page":"3214","volume":"9","author":"W Song","year":"2015","unstructured":"Song W, Zhang K, Dong LP, Lu W, Li CG, Luan J. Association between YKL-40 and type 2 diabetic microangiopathy. Chinese J Clin. 2015;9:3214\u20138.","journal-title":"Chinese J Clin"},{"key":"624_CR25","first-page":"75","volume":"13","author":"KJ Ye","year":"2016","unstructured":"Ye KJ, Hao Q, Dai J, Ye XJ. Association between YKL-40 and gestational diabetes mellitus. China medical herald. 2016;13:75\u20138.","journal-title":"China medical herald"},{"key":"624_CR26","first-page":"78","volume":"12","author":"QF Chen","year":"2014","unstructured":"Chen QF, Yi ZG, Guo WA. Association between YKL-40 and type 2 diabetes as well as lower extremity atherosclerosis. Guide China Med. 2014;12:78\u20139.","journal-title":"Guide China Med"},{"key":"624_CR27","first-page":"2300","volume":"27","author":"P Li","year":"2011","unstructured":"Li P, Gao JD, Zhang HL, Ma SH, Du CG. Expression of YKL-40 and Chemerin in chronic complications of type 2 diabetes mellitus. Modern Med Health. 2011;27:2300\u20132.","journal-title":"Modern Med Health"},{"issue":"118\u201321","key":"624_CR28","first-page":"129","volume":"40","author":"LJ Lin","year":"2019","unstructured":"Lin LJ, Fan PY, Yao YL, Luo W, Jiang YP, Song K, et al. The relationship between serum YKL-40 and type 2 diabetic retinopathy and diabetic nephropathy. Chinese High Altit Med Biol. 2019;40(118\u201321):129.","journal-title":"Chinese High Altit Med Biol"},{"key":"624_CR29","first-page":"52","volume":"10","author":"SL Xun","year":"2017","unstructured":"Xun SL, Hu JJ, Chen J, Zhang LL, Lu HM, Kong X. Expression and significance of YKL-40 in maternal blood and umbilical cord blood serum and placenta in patients with gestational diabetes mellitus. China Foreign Med Treat. 2017;10:52\u20135.","journal-title":"China Foreign Med Treat"},{"key":"624_CR30","first-page":"17","volume":"39","author":"YY Yu","year":"2018","unstructured":"Yu YY, Shi X, Pan JQ, Shi WW, Tan LY, Yu XJ. Study on the correlation between serum A-FABP and YKL-40 levels and insulin resistance in newly diagnosed T2DM patients. J Liaoning Med Univ. 2018;39:17\u201321.","journal-title":"J Liaoning Med Univ"},{"key":"624_CR31","first-page":"27","volume":"20","author":"LY Ren","year":"2019","unstructured":"Ren LY, Wang YZ, Wei CY, Liu Y, Zheng LM. Correlation between levels of lipoprotein-associated phospholipase A2 and chitinase 3-like protein 1 with diabetes retinopathy in type 2 diabetes mellitus. China Health Standard Managem. 2019;20:27\u201330.","journal-title":"China Health Standard Managem"},{"key":"624_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2337\/dc08-1144","volume":"32","author":"CN Rathcke","year":"2009","unstructured":"Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32:323\u20138.","journal-title":"Diabetes Care"},{"key":"624_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1475-2840-10-54","volume":"10","author":"AK Rondbjerg","year":"2011","unstructured":"Rondbjerg AK, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovascu Diabetol. 2011;10:54.","journal-title":"Cardiovascu Diabetol"},{"key":"624_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jdiacomp.2012.04.012","volume":"26","author":"JH Lee","year":"2012","unstructured":"Lee JH, Kim SS, Kim IJ, Song SH, Kim YK, In Kim J, et al. Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. J Diabetes Complicat. 2012;26:308\u201312.","journal-title":"J Diabetes Complicat"},{"key":"624_CR35","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.imbio.2018.07.020","volume":"223","author":"D Umapathy","year":"2018","unstructured":"Umapathy D, Dornadula S, Krishnamoorthy E, Mariappanadar V, Viswanathan V, Ramkumar KM. YKL-40: A biomarker for early nephropathy in type 2 diabetic patients and its association with inflammatory cytokines. Immunobiology. 2018;223:718\u201327.","journal-title":"Immunobiology"},{"key":"624_CR36","first-page":"720","volume":"23","author":"HJ Zhu","year":"2015","unstructured":"Zhu HJ, Yang MM, Cheng L, Zhu X, Cheng XB. The changes and clinical significance of serum YKL-40 level in type 2 diabetic patients with chronic kidney disease. Chinese J Diabetes. 2015;23:720\u20132.","journal-title":"Chinese J Diabetes"},{"key":"624_CR37","first-page":"57","volume":"16","author":"H Wang","year":"2015","unstructured":"Wang H, Cui K, Xu K, Fang XX. Relationship between serum YKL-40 and atherosclerosis in patients with type 2 diabetic nephropathy. Chinese J Integrat Tradit Western Nephrol. 2015;16:57\u20138.","journal-title":"Chinese J Integrat Tradit Western Nephrol"},{"key":"624_CR38","first-page":"1110","volume":"11","author":"ZX Yu","year":"2017","unstructured":"Yu ZX, Wang YZ. YKL-40 and MPV in the clinical value of early diabetic nephropathy. Chinese J Clin. 2017;11:1110\u20133.","journal-title":"Chinese J Clin"},{"key":"624_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"624_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"624_CR41","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/sim.4780070807","volume":"7","author":"RF Galbraith","year":"1988","unstructured":"Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889\u201394.","journal-title":"Stat Med"},{"key":"624_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"624_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00044067-199811000-00009","volume":"9","author":"NJ Morwessel","year":"1998","unstructured":"Morwessel NJ. The genetic basis of diabetes mellitus. AACN Clin Issues. 1998;9:539\u201354.","journal-title":"AACN Clin Issues"},{"key":"624_CR44","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.2337\/diacare.27.11.2769","volume":"27","author":"A Treszl","year":"2004","unstructured":"Treszl A, Szereday L, Doria A, King GL, Orban T. Elevated C-reactive protein levels do not correspond to autoimmunity in type 1 diabetes. Diabetes Care. 2004;27:2769\u201370.","journal-title":"Diabetes Care"},{"key":"624_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s125-002-8256-1","volume":"45","author":"T Temelkova-Kurktschiev","year":"2002","unstructured":"Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance. Diabetologia. 2002;45:151.","journal-title":"Diabetologia"},{"key":"624_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2337\/diabetes.51.2.455","volume":"51","author":"B Vozarova","year":"2002","unstructured":"Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455\u201361.","journal-title":"Diabetes"},{"key":"624_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327\u201334.","journal-title":"JAMA"},{"key":"624_CR48","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1902\/jop.2008.080246","volume":"79","author":"GL King","year":"2008","unstructured":"King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527\u201334.","journal-title":"J Periodontol"},{"key":"624_CR49","first-page":"598","volume":"9","author":"C \u00d8stergaard","year":"2002","unstructured":"\u00d8stergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol. 2002;9:598\u2013604.","journal-title":"Clin Diagn Lab Immunol"},{"key":"624_CR50","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1136\/ard.59.7.544","volume":"59","author":"K Vos","year":"2000","unstructured":"Vos K, Steenbakkers P, Miltenburg AM, Bos E, van Den Heuvel MW, van Hogezand RA, et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2000;59:544\u20138.","journal-title":"Ann Rheum Dis"},{"key":"624_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1172\/JCI27280","volume":"116","author":"JG Neels","year":"2006","unstructured":"Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Investig. 2006;116:33\u20135.","journal-title":"J Clin Investig"},{"key":"624_CR52","first-page":"E60","volume":"264","author":"PM Catalano","year":"1993","unstructured":"Catalano PM, Tyzbir ED, Wolfe RR, Calles J, Roman NM, Amini SB, et al. Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes. Am J Physiol. 1993;264:E60\u20137.","journal-title":"Am J Physiol"},{"key":"624_CR53","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0002-9378(99)70662-9","volume":"180","author":"PM Catalano","year":"1999","unstructured":"Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol. 1999;180:903\u201316.","journal-title":"Am J Obstet Gynecol"},{"key":"624_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225\u201332.","journal-title":"Kidney Int"},{"key":"624_CR55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/bmj.296.6616.156","volume":"296","author":"HH Parving","year":"1988","unstructured":"Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ. 1988;296:156\u201360.","journal-title":"BMJ"},{"key":"624_CR56","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s001250100000","volume":"44","author":"ME Cooper","year":"2001","unstructured":"Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957\u201372.","journal-title":"Diabetologia"},{"key":"624_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrneph.2011.51","volume":"7","author":"JF Navarro-Gonzalez","year":"2011","unstructured":"Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327\u201340.","journal-title":"Nat Rev Nephrol"},{"key":"624_CR58","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20050025","volume":"109","author":"CG Schalkwijk","year":"2005","unstructured":"Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143\u201359.","journal-title":"Clin Sci"},{"key":"624_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2362.2010.02446.x","volume":"41","author":"JM Brix","year":"2011","unstructured":"Brix JM, Hollerl F, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 in type 2 diabetic patients with different levels of albuminuria. Eur J Clin Invest. 2011;41:589\u201396.","journal-title":"Eur J Clin Invest"},{"key":"624_CR60","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.diabres.2010.11.015","volume":"91","author":"T Yasuda","year":"2011","unstructured":"Yasuda T, Kaneto H, Katakami N, Kuroda A, Matsuoka TA, Yamasaki Y, et al. YKL-40, a new biomarker of endothelial dysfunction, is independently associated with albuminuria in type 2 diabetic patients. Diabetes Res Clin Pract. 2011;91:e50\u20132.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-021-00624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13098-021-00624-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-021-00624-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T12:50:08Z","timestamp":1670763008000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-021-00624-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1186\/s13098-021-00624-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-66065\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-66065\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-66065\/v1","asserted-by":"object"}]},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"If the manuscript is accepted, we approve it for publication in Diabetology & Metabolic Syndrome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}